Locations:
Search
Risk does not end after the acute phase is over.
Study finds no evidence that dual coverage lowers risk of surgical site infection
Infliximab-abda offers similar benefits at lower costs
More accurate than existing noninvasive tests
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
A cost-effective alternative to enoxaparin?
Results of the largest population-based study to date
Rates similar for both methods
Multicenter observational study shows no simple answer
Measuring outcomes becomes more granular with surgeon-entered data
Challenging an old surgical standard
Advertisement
Advertisement